导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.80% | 1750/4773 |
| 近一周 | -1.87% | 3043/5465 |
| 近一月 | -5.17% | 3647/5421 |
| 近一季 | -10.74% | 3818/5231 |
| 近半年 | -3.63% | 2527/4920 |
| 近一年 | 7.69% | 1437/4394 |
| 近两年 | 62.91% | 1170/2954 |
| 近三年 | 39.16% | 788/2253 |
| 成立以来 | 139.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.51% 1252/4961 |
17.23% 1483/5312 |
- - |
- - |
| 2025 | 28.25% 1499/4813 |
1.43% 1625/3635 |
-0.96% 3076/4076 |
26.59% 1343/4524 |
0.85% 1717/4813 |
| 2024 | 13.11% 1177/3463 |
2.26% 802/2808 |
-1.39% 1056/3014 |
15.36% 1734/3129 |
-2.77% 2180/3463 |
| 2023 | -12.54% 1485/2656 |
4.46% 945/2280 |
-4.86% 1311/2385 |
-6.02% 1415/2515 |
-6.35% 1733/2655 |
| 2022 | -24.93% 1273/2207 |
-19.50% 1466/1919 |
7.69% 439/2016 |
-15.16% 1230/2113 |
2.07% 1047/2208 |
| 2021 | 1.51% 669/1822 |
-5.55% 933/1255 |
13.30% 292/1330 |
-6.55% 956/1466 |
1.51% 898/1822 |
| 2020 | 51.80% 157/1250 |
-3.59% 310/1028 |
24.32% 173/1067 |
9.10% 672/1164 |
16.08% 183/1184 |
| 2019 | 39.44% 281/1092 |
31.60% 197/754 |
-5.19% 456/804 |
2.41% 300/850 |
9.12% 257/918 |
| 2018 | -31.07% 488/834 |
- - |
- - |
- - |
-12.65% 466/691 |
| 2017 | 12.42% 277/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.28% 412/605 |
- - |
- - |
- - |
- - |
| 2015 | 36.43% 52/575 |
- - |
- - |
- - |
- - |
| 2014 | 30.49% 162/237 |
- - |
- - |
- - |
- - |
| 2013 | 7.74% 42/186 |
- - |
- - |
- - |
- - |
| 2012 | -3.32% 137/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 大摩深证300指数增强 VS. 长安沪深300非周期A(740101) |